Please assess the completion status of the following clinical trial:

Trial Title: Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-65 years old;~2. Willing and able to provide informed consent, attend all study visits, and comply with the protocol;~3. Daily smoker for at least one year; and~4. Currently smoke an average of at least 5 cigarettes per day.~Exclusion Criteria:~1. Current diagnosis of a psychotic, eating, developmental or bipolar disorder, or significant suicide risk;~2. Current treatment for smoking cessation or use of other nicotine products, including e-cigarettes;~3. Exclusion criteria related to isradipine administration: (a) known allergy or sensitivity to isradipine, (b) hypertension, (c) congestive heart failure, (d) any type of liver disease, (e) current pregnancy, (f) women of childbearing potential who are not using medically accepted forms of contraception, (g) current use of Rifampin, which decreases the availability of calcium channel blockers, or of Tagamet, which can increase hypotensive effects and inhibit hepatic metabolism of isradipine, (h) any other significant medical condition that increases risk, as determined by the study physician;~4. Significant vision problems that would prevent engagement with the 360° video environment; and~5. Past six month substance use disorder, other than nicotine use disorder, assessed by structured interview.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- isradipine (Type: EXPERIMENTAL): Participants will receive 15mg of immediate release isradipine.
- placebo (Type: PLACEBO_COMPARATOR): Participants will receive a placebo pill identical in appearance to isradipine.

Based on this trial design, predict the completion outcome and termination type (if applicable).